Royalty Pharma PLC
Royalty Pharma's GHG Emissions Data Preview
In 2024, Royalty Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 3 (indirect emissions across the value chain).
Royalty Pharma has also provided a category-level breakdown for 1 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy/Paste is a PRO feature.  | Copy/Paste is a PRO feature. | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy/Paste is a PRO feature. | 0000000 | Copy/Paste is a PRO feature. | 0000000 |
Location-Based | Copy/Paste is a PRO feature. | 0000000 | Copy/Paste is a PRO feature. | 0000000 |
Total Scope 3 | Copy/Paste is a PRO feature.  a | Copy/Paste is a PRO feature.  a | 0000000 | 0000000 |
Verified Sources Behind Royalty Pharma’s Greenhouse Gas (GHG) Emissions Data
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Royalty Pharma’s data sources below and access millions more through our Disclosure Search.
Insights into Royalty Pharma's Operational Emissions
No operational GHG emissions data disclosed for Royalty Pharma in 2024.
NaNInsights into Royalty Pharma's Value Chain Emissions
In 2024, Royalty Pharma reported 23,266 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Royalty Pharma includes a breakdown across 1 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
Royalty Pharma's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Royalty Pharma's Scope 3 emissions?
In 2024, Royalty Pharma reported total Scope 3 emissions of 23,266 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 0% of these emissions originated from upstream activities such as purchased goods and capital goods, while 100% came from downstream activities like product use, distribution, and end-of-life treatment.a
Has Royalty Pharma reduced its Scope 3 emissions over time?
Since 2021, Royalty Pharma's Scope 3 emissions have increased by 26.14%, reflecting a rising long-term trend in Scope 3 emissions over time.ab
Compared to the previous year (2023), Royalty Pharma's Scope 3 emissions decreased by 27.3%, highlighting the company's efforts to lower indirect emissions from its value chain.a
What categories of Scope 3 emissions does Royalty Pharma disclose?
In 2024, Royalty Pharma reported emissions for 1 out of the 15 Scope 3 categories defined by the GHG Protocol.a
The limited disclosure restricts visibility into specific emission sources across the company's value chain.
What are the main sources of Royalty Pharma's Scope 3 emissions?
In 2024, the largest contributors to Royalty Pharma's Scope 3 emissions were:a
- Investments (Cat. 15): 23,266 tCO₂e (100%)